Hybrigenics appoints Eric Castaldi to board
This article was originally published in Scrip
Executive Summary
Hybrigenics, a French biopharmaceutical company focusing on the R&D of new cancer treatments, has appointed Eric Castaldi to its board as a non-executive independent director. He is chief financial officer and a member of the executive committee at NicOx.